Analysis finds oncology trials may lack rigor

05/7/2013 | PharmaTimes (U.K.)

An analysis of nearly 9,000 clinical trials of cancer therapies conducted between 2007 and 2010 found the trials tend to be smaller and less robust than trials for therapies in other disease areas. The Duke University analysis was part of the FDA's Clinical Trials Transformation Initiative to improve the quality and efficiency of clinical trials. Oncology trials tended to be small, early-stage and nonrandomized, researchers reported in JAMA Internal Medicine.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA